Genotyping HLA‐B*5801 for Allopurinol‐Induced Severe Cutaneous Adverse Reactions: An Accurate and Prompt Method. Issue 6 (14th December 2015)

• Record Type: Journal Article
• Authors: Cheng, Lin; Zhang, Lihua; Gao, Lichen; Zhang, Wei; Chen, Xiaoping; Zhou, Hong‐Hao
• Is Part Of: Clinical and translational science. Volume 8:Issue 6(2015)
• Page Start: 834
• Page End: 836
• Publication Date: 2015-12-14
• Subjects: allopurinol -- severe cutaneous adverse reactions (SCARs) -- HLA‐B*5801 -- genotyping; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.12365
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract: Objectives: A new method of HLA‐B*5801 genotyping was compared with sequence‐based typing (SBT) to find an accurate and prompt method in genotyping HLA‐B*5801 . Methods: Two groups of patients from allopurinol‐induced cutaneous adverse reactions (SCARs) and allopurinol‐tolerant were both genotyped with PG5801 kit and SBT method. The genotyping results of HLA‐B*5801 were compared between the two groups. Results: The PG5801 detection kit results were 100% (79/79) in agreement with the SBT genotyping results for identifying the HLA‐B*5801 (+) patients. No false‐positive or false‐negative errors were found. The sensitivity, specificity, rate of adherence, positive predictive value (PPV) and negative predictive value (NPV) were 100%. Conclusion: The potential fast screening method is an ideal tool to rule out the high‐risk allopurinol‐induced SCARs patients.